Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
Central Serous Chorioretinopathy
/ diagnosis
Choroid
Chronic Disease
Eplerenone
/ therapeutic use
Fluorescein Angiography
Humans
Photochemotherapy
Photosensitizing Agents
/ therapeutic use
Porphyrins
/ therapeutic use
Retrospective Studies
Tomography, Optical Coherence
Verteporfin
/ therapeutic use
Visual Acuity
Chronic central serous chorioretinopathy
eplerenone
half-fluence photodynamic therapy
neurosensory detachment
subfoveal choroidal thickness
Journal
European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
pubmed:
30
1
2021
medline:
24
11
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
To compare the long-term outcomes in chronic central serous chorioretinopathy (cCSC) following half-fluence photodynamic therapy (HF-PDT) and oral eplerenone treatment. This retrospective comparative study included consecutive patients of cCSC treated with either HF-PDT or eplerenone. The treatment outcomes of the two groups were analyzed at 3-month, 6-month, and 12-month post-treatment. This study included 20 eyes (20 patients) in HF-PDT group, and 18 eyes (18 patients) in eplerenone group. All baseline parameters in HF-PDT and eplerenone groups were comparable including neurosensory detachment height (217.05 ± 140.25 µm vs 178.05 ± 164.24 µm respectively, HF-PDT has a superior efficacy to achieve faster, greater and long-lasting resolution of subretinal fluid in cCSC compared to eplerenone therapy.
Identifiants
pubmed: 33508971
doi: 10.1177/1120672121991053
doi:
Substances chimiques
Photosensitizing Agents
0
Porphyrins
0
Verteporfin
0X9PA28K43
Eplerenone
6995V82D0B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM